Speculating here. If one trial if one trial in Europe is the outcome - and seems due "in next few weeks" (given hx likely in December) - what do you think the market will do? On one hand, we have appx 60% of addressable market in the EU and a quicker path to commercialisation event.
One the other hand FDA seems to be a key to the market opinion.
My opinion, will be a decent but not over the top re-rate to if one trial in EU. Appx $1.
I think this firms as the likely scenario.
Like to hear your thoughts.
Speculating here. If one trial if one trial in Europe is the...
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
